Cytokeratin expression in breast cancer: Phenotypic changes associated with disease progression

Cytometry

Volumn 32, Issue 4, 1998, Pages 301-308

  Brotherick, Ian ^a,c   Robson, C N ^a   Browell, D A ^b   Shenfine, J ^b   White, M D ^a   Cunliffe, W J ^b   Shenton, B K ^a   Egan, M ^b   Webb, L A ^b   Lunt, L G ^b   Young, J R ^b   Higgs, M J ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Breast; Cancer; Cytokeratin; Flow cytometry

Indexed keywords

CYTOKERATIN;

ANTIBODY SPECIFICITY; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CELL INFILTRATION; CYTOSKELETON; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERMEDIATE FILAMENT; LYMPH NODE METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0032145883     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(19980801)32:4<301::AID-CYTO7>3.0.CO;2-K     Document Type: Article

References (35)

1. Angus B, Purvis J, Stock, D, Westley BR, Samson ACR, Routledge EG, Carpenter FH, Horne CHW: NCL-5D3: A new monoclonal antibody recognising low molecular weight cytokeratins effective for immunohistochemistry using fixed paraffin-embedded tissue. J Pathol 153:377-384, 1987.
2. Bartek J, Taylor-Papadimitriou J, Miller N, Millis R: Patterns of expression of keratin 19 as detected with monoclonal antibodies in human breast tissues and tumors. Int J Cancer 36:299-306, 1985.
3. Betts AM, Waite I, Neal DE, Robson CN: Androgen regulation of ornithine decarboxylase in human prostatic cells identified using differential display. FEBS Lett 405:328-332, 1997.
4. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 35:299-306, 1957.
5. Brotherick I, Lennard TWJ, Wilkinson SE, Cook S, Angus B, Shenton BK: Flow cytometric method for the measurement of epidermal growth factor receptor and comparison with the radio-ligand binding assay. Cytometry 16:262-269, 1994.
6. Brotherick I, Lennard TWJ, Cook S, Johnstone R, Angus B, Winthreik MP, Shenton BK: Use of the biotinylated antibody DAKO-ER 1D5 to measure oestrogen receptor on cytokeratin positive cells obtained from primary breast cancer cells. Cytometry 40:74-80, 1995.
7. Brotherick I, Shenton BK, Lennard TWJ: Are fine needle aspirates representative of the underlying solid tumor? A comparison of receptor levels, ploidy and the influence of cytokeratin gates. Br J Cancer 72:732-737, 1995.
8. Brotherick I, Shenton BK, Cowan WK, Angus B, Horne CHW, Higgs MJ, Lennard TWJ: The relationship between flow-cytometric and immunohistochemically detected c-erbB-2 expression, grade and DNA ploidy in breast cancer. Cancer Immunol Immunother 41:137-145, 1995.
9. Bundred NJ, Morgan DAL, Dixon JM: Management of regional nodes in breast cancer. BMJ 309:1222-1225, 1994.
10. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Analytical Bioch 162:156-159, 1987.
11. Chu YW, Runyan RB, Oshima RG, Hendrix MJ: Expression of complete keratin filaments in mouse L cell migration and invasion. Proc Natl Acad Sci USA 90:4261-4265, 1993.
12. Clevenger CV, Khandewal M, Stadtmauer E, Jardines L: Detection of bone marrow metastasis using multi parameter flow cytometry. Ann N Y Acad Sci 677:400-401, 1993.
13. Coombes RC, Powles TJ, Gazet J-C, Nash AG, Ford HT, McKinna A, Neville AM: Assessment of biochemical tests to screen for metastases in patients with breast cancer. Lancet 1:296-298, 1980.
14. Diaz-Guerra M, Haddow S, Bauluz C, Jorcano JI, Cano A, Balmain A, Quintanilla M: Expression of simple epithelial cytokeratins in mouse keratinocytes harboring Harvey ras gene alterations. Cancer Res 52:680-687, 1992.
15. Ferrero M, Spyratos F, Le Doussal V, Desplaces A, Rouëssé J: Flow cytometric analysis of DNA content and keratins by using CK7, CK8, CK18, CK19, and KL1 monoclonal antibodies in benign and malignant tumors. Cytometry 11:716-724, 1990.
16. Fields KK, Elfenbein GJ, Trudeau WI, Perkins JB, Janssen WE, Moscinski LC: Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 14:1868-1876, 1996.
17. Fisher B: Relation of number of positive axillary nodes to prognosis of patients with primary breast cancer. Cancer 52:1551-1557, 1983.
18. Galea MH, Blamey RW, Elston CE, Ellis I: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22:207-219, 1992.
19. Glogovac JK, Porter PL, Banker DE, Rabinovitch PS: Cytokeratin labeling of breast cancer cells extracted from paraffin-embedded tissue for bivariate flow cytometric analysis. Cytometry 24:260-267, 1996.
20. Heatley M, Maxwell P, Whiteside C, Toner P: Cytokeratin intermediate filament expression in benign and malignant breast disease. J Clin Pathol 48:26-32, 1995.
21. Hembrough TA, Kralovich KR, Li L, Gonias SL: Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen activator and promotes plasminogen activation. J Cell Sci 108:1071-1082, 1995.
22. Jarasch ED, Nagle RB, Kaufmann M, Maurer C, Bocker WJ: Differential diagnosis of benign epithelial proliferation and carcinomas of the breast using antibodies to cytokeratins. Hum Pathol 3:276-288, 1988.
23. Jing Y, Zhang J, Waxman S, Mira-Y-Lopez R: Up regulation of cytokeratins 8 and 18 in human breast cancer T47D cells is retinoid specific and retinoic acid receptor-dependent. Differentiation 60:109-117, 1996.
24. Moll R, Franke WW, Schiller DL, Geiger B, Kreiper R: The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors, and cultured cells. Cell 31:11-24, 1982.
25. Richards MA, Smith IE, Dixon JM: Role of systemic treatment for primary operable breast cancer. BMJ 309:1363-1366, 1984.
26. Schaller G, Fuchs J, Pritze W, Ebert A, Herbst H, Pantel K, Weitzel H, Lengyel E: Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Rev 2:1879-1885, 1996.
27. Schoenfeld A, Luqmani Y, Sinnett HD, Shousha S, Coombes RC: Keratin 19 mRNA measurement to detect micro metastases in lymph nodes in breast cancer. Br J Cancer 74:1639-1642, 1996.
28. Shankey TV: Antibodies to intermediate filament proteins as probes for multi parameter flow cytometry of human cancers. In: Clinical Flow Cytometry: Principles and Applications, Bauer D (ed). Williams & Wilkins, Baltimore, 1992, pp. 209-229.
29. Silverberg SG: Staging in the therapy of cancer of the breast. Am J Clin Pathol 64:756-760, 1975.
30. Su L, Morgan PR, Lane EB: Expression of cytokeratin messenger RNA versus protein in the normal mammary gland and in breast cancer. Hum Pathol 27:800-806, 1996.
31. Takei H, Lino Y, Horiguchi J, Kanoh T, Takao Y, Oyama T, Morishita Y: Immunohistochemical analysis of cytokeratin number 8 as a prognostic factor in invasive breast carcinoma. Anticancer Res 15:1101-1105, 1995.
32. Visscher DW, Zarbo RJ, Green A, Crissman JD: Prognostic significance of morphological parameters and flow cytometric DNA analysis in carcinoma of the breast. Pathol Ann 25:171-210, 1990.
33. Whiteside TL, Miescher S, Hurlimann J, Moretta L, Von Fliedner V: Clonal analysis and in situ characterization of lymphocytes infiltrating human breast carcinomas. Cancer Immunol Immunother 23:169-178, 1986.
34. Wingren S, Stal O, Nordenskjold A: Flow cytometric analysis of s-phase fraction in breast carcinomas using gating on cells containing cytokeratin. Br J Cancer 69:546-549, 1994.
35. Wong LS, Bateman WJ, Morris AG, Fraser IA: Detection of circulating tumor cells with the magnetic activated cell sorter. Br J Surg 82:1333-1337, 1995.